CUPERTINO, Calif.–(BUSINESS WIRE)–BioImagene, a leading provider of innovative imaging software and systems for cancer diagnosis and research is pleased to announce Dr. Joseph Keegan’s appointment as a director to the company’s board.
Dr. Keegan brings over 25 years’ management experience in the life sciences tools industry. He is currently the President and CEO of ForteBio Inc. Previously Dr. Keegan was the CEO of Molecular Devices (MDC). During his 9-year tenure at MDC, Dr. Keegan grew the company’s revenues from $30 million to $190 million and in early 2007 he oversaw its acquisition by MDS for $615 million. Prior to MDC, Dr. Keegan served in Becton Dickinson and company as President of Worldwide Tissue Culture. His executive management experience also includes Leica, Inc. where he was Vice President of Microscopy and Scientific Instruments Division.
“It is a pleasure to welcome Dr. Keegan to our Board at a time when the company is experiencing significant growth. Joe’s extensive medical device experience and proven track record of building and managing life science companies will be a significant asset to Bioimagene and its board of directors. Joe’s appointment will strengthen the board’s ability to effectively guide BioImagene in its efforts to become a leading digital pathology solutions company,” said Mohan Uttarwar, BioImagene CEO.
“I am pleased about my appointment to the BioImagene Board at this stage of the company’s development. It is an exciting time as more companies and laboratories are using digital pathology systems. BioImagene is well positioned to increase its market presence with a strong product pipeline. I look forward to helping BioImagene expand its successful business,” commented Dr. Keegan.
